Finch Therapeutics Group
VerifiedA clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs.
Launch date
Employees
Market cap
$2.9m
Net debt
($8.8m)
Enterprise valuation
$12m (Public information from May 2024)
Share price
$0.967 FNCH
Somerville Massachusetts (HQ)
Deals in current and previous year:
| USD | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | (24 %) | 140 % | (95 %) | (88 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (202 %) | (500 %) | (324 %) | (8670 %) | 16219 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (204 %) | (510 %) | (314 %) | (13315 %) | (69864 %) |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 232 % | 429 % | 309 % | 6724 % | 6728 % |
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | $0.0 | round |
| investor | $0.0 | round | |
| N/A | $0.0 | round | |
| investor investor investor | $0.0 | round | |
| investor investor investor investor | $0.0 | round | |
| investor investor investor investor investor investor investor investor investor investor investor investor investor | $0.0 | round | |
| N/A | $125m | IPO | |
| Total Funding | 000k | ||
